With GlaxoSmithKline’s megablockbuster Advair soon to be experiencing fierce generic competition, investors were assured that the pharma giant had another remedy in hand. Excitement built around Breo Ellipta, a drug developed to improve the mortality rate of high-risk patients with COPD, but the product hasn’t exactly played out as planned. Will the company be able to survive with its recent R&D track record? Read more here. (Source: John Carrol, FierceBiotech, 9/8/15)
Connected. Community.
